Sermorelin in Special Populations: An Evidence-Transfer Map

The Historical Product Matters

Sermorelin is a synthetic 29-amino-acid fragment of human growth hormone–releasing hormone. FDA records show two discontinued Geref presentations: one used to evaluate pituitary growth-hormone secretion and another indicated for idiopathic growth-hormone deficiency in children with growth failure. The sponsor notified FDA in 2008 that the products were being discontinued; FDA withdrew the approvals effective June 18, 2009.

FDA later reviewed its files and stated that the two named GEREF products “were not withdrawn from sale for reasons of safety or effectiveness.”

The issuer is the U.S. Food and Drug Administration, signed by Assistant Commissioner for Policy Leslie Kux. This 11-word verbatim fragment appears in the FDA determination paragraph on physical page 4 of the public-inspection PDF, extraction lines 84–85. It clarifies why the historical products left the market; it does not endorse modern sermorelin prescribing, compounded products, or HealthRX.com (FDA notice, 78 FR, March 4, 2013, lines 84–85/page 4).

“Not withdrawn for safety or effectiveness” is not the same as “currently approved,” “proven for anti-aging,” or “appropriate for every population.” It is a regulatory determination about the reason for discontinuation.

The Evidence-Transfer Matrix

The matrix prevents “same pathway” from becoming “same medicine.” Tesamorelin is a different GHRH analogue with an FDA-approved indication for reducing excess abdominal fat in adults with HIV lipodystrophy; somatropin is growth hormone itself. Their labels can highlight questions worth asking, but they cannot supply missing sermorelin trials.

Children: Historical Evidence Is Real but Narrow

A 1999 review found limited data supporting daily subcutaneous sermorelin in some prepubertal children with idiopathic growth-hormone deficiency, while noting that final adult height had not been determined and direct comparison with somatropin was lacking (Prakash and Goa, PMID 18031173; DOI 10.2165/00063030-199912020-00007).

That literature belongs to diagnosed pediatric endocrine disease and a historical regulated product. It does not support height enhancement in children without deficiency, home interpretation of growth charts, or dosing from an adult wellness clinic. Growth failure can reflect nutrition, thyroid disease, chronic inflammation, genetic conditions, delayed puberty, skeletal disorders, or other causes; evaluation precedes treatment.

The pediatric sermorelin safety page should be read as a separate evidence question, not as confirmation that a current product is approved.

Older Adults and “Anti-Aging”: The Missing Outcome Problem

Age-related changes in growth hormone and IGF-1 do not by themselves diagnose adult growth-hormone deficiency. The Endocrine Society guideline recommends stimulation testing in most adults when deficiency is suspected and reserves treatment decisions for appropriately diagnosed patients, with attention to risks and individualized monitoring (Molitch et al., PMID 21602453; DOI 10.1210/jc.2011-0179). The guideline evaluates growth hormone replacement—not compounded sermorelin as an anti-aging treatment.

No responsible trial record identified here establishes that chronic sermorelin improves lifespan, cognition, frailty, cardiovascular outcomes, or independent living in healthy older adults. A rise in a hormone marker is not a patient-centered benefit. The older-adult sermorelin safety review separates age from diagnosed pituitary disease.

Pregnancy and Lactation: Absence Is Not Reassurance

No adequate modern human pregnancy or lactation dataset for sermorelin was identified. There is no evidence-based fetal-risk estimate, milk-transfer estimate, or pregnancy dosing protocol. Related growth-hormone-axis products have their own labeling, but a tesamorelin or somatropin instruction cannot be silently transferred to sermorelin.

Anyone pregnant, planning pregnancy, or breastfeeding should disclose the exact product and source to the obstetric and endocrine teams. A nonapproved injectable adds product-identity, sterility, potency, and impurity questions beyond the active peptide. The pregnancy and lactation evidence page covers that narrower decision.

Cancer, Diabetes, and Pituitary Disease Need Specialist Framing

Sermorelin acts upstream of growth hormone and IGF-1. That makes active malignancy, prior tumor history, intracranial disease, abnormal pituitary function, glucose intolerance, edema, sleep apnea, and proliferative retinopathy clinically relevant review domains. It does not establish that sermorelin caused or will accelerate a specific cancer, nor does it create a universal IGF-1 cutoff.

Current Egrifta SV labeling—again, for tesamorelin rather than sermorelin—contraindicates active malignancy and warns about elevated IGF-1, glucose intolerance or diabetes, fluid retention, and hypersensitivity (FDA Egrifta SV label, 2024, sections 4 and 5). These are useful prompts for specialist review, not a substitute sermorelin label.

Kidney and Liver Impairment: No Dose Table to Copy

The legacy page supplied renal and hepatic monitoring plans without a dedicated modern sermorelin pharmacokinetic study. Organ impairment can alter fluid balance, glucose control, nutrition, medication exposure, and the interpretation of IGF-1 and other laboratory results. That complexity supports individualized review, not a fixed percentage dose reduction.

The exact diagnosis and severity, dialysis or transplant status, current medicines, edema, blood pressure, glucose control, and treatment goal all matter. See the separate renal-impairment evidence review and hepatic-impairment evidence review for source-specific boundaries.

Compounding Changes the Evidence Question

FDA says compounded drugs are not FDA-approved and are not reviewed for safety, effectiveness, or quality before marketing. Poor compounding can create contamination, strength, and purity problems (FDA, Understanding the Risks of Compounded Drugs).

The 2013 Geref determination allows a legal pathway for abbreviated applications if requirements are met; it is not categorical permission for any pharmacy, bulk substance, formulation, or clinical use. Compounding legality depends on facts beyond the old product’s discontinuation reason. Product sourcing should therefore be documented rather than represented as equivalent to historical Geref.

What the Legacy Page Got Wrong

The previous version treated sermorelin as routinely available through compounding, borrowed tesamorelin, somatropin, HIV, transplant, geriatric, renal, and hepatic rules into a unified protocol, and supplied unsupported monitoring schedules. It also flattened the regulatory history into “withdrawn in 2008,” omitting FDA’s later reason determination and the 2009 effective withdrawal date.

This revision preserves the clinically consequential populations while making evidence transfer visible. A historical pediatric or diagnostic record cannot carry modern adult-wellness claims across the line.

Medical review of this revision is pending. FDA, the Endocrine Society, investigators, authors, journals, manufacturers, pharmacies, and institutions do not endorse sermorelin products, HealthRX.com, or this page.